DK1060750T3 - Propan-1,3-disulfonsyre og dens farmaceutisk acceptable salte til behandling af amyloidose - Google Patents

Propan-1,3-disulfonsyre og dens farmaceutisk acceptable salte til behandling af amyloidose

Info

Publication number
DK1060750T3
DK1060750T3 DK00202287T DK00202287T DK1060750T3 DK 1060750 T3 DK1060750 T3 DK 1060750T3 DK 00202287 T DK00202287 T DK 00202287T DK 00202287 T DK00202287 T DK 00202287T DK 1060750 T3 DK1060750 T3 DK 1060750T3
Authority
DK
Denmark
Prior art keywords
groups
pharmaceutically acceptable
amyloidosis
propane
treatment
Prior art date
Application number
DK00202287T
Other languages
English (en)
Inventor
Robert Kisilevsky
Donald Weaver
Walter Szarek
Original Assignee
Univ Kingston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kingston filed Critical Univ Kingston
Application granted granted Critical
Publication of DK1060750T3 publication Critical patent/DK1060750T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/06—Use of macromolecular materials
    • A61L33/08—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Surgery (AREA)
  • Psychiatry (AREA)
  • Materials Engineering (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00202287T 1993-03-29 1994-03-29 Propan-1,3-disulfonsyre og dens farmaceutisk acceptable salte til behandling af amyloidose DK1060750T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3784493A 1993-03-29 1993-03-29

Publications (1)

Publication Number Publication Date
DK1060750T3 true DK1060750T3 (da) 2006-01-09

Family

ID=21896688

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00202287T DK1060750T3 (da) 1993-03-29 1994-03-29 Propan-1,3-disulfonsyre og dens farmaceutisk acceptable salte til behandling af amyloidose

Country Status (8)

Country Link
EP (3) EP1060750B1 (da)
JP (2) JP3666818B2 (da)
AT (1) ATE311864T1 (da)
CA (1) CA2159326C (da)
DE (1) DE69434571T2 (da)
DK (1) DK1060750T3 (da)
ES (1) ES2251935T3 (da)
WO (1) WO1994022437A2 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
US20040208875A1 (en) 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
US5858326A (en) * 1995-06-06 1999-01-12 Neurochem, Inc. Methods of increasing amyloid deposition
US6001331A (en) * 1996-01-24 1999-12-14 Warner-Lambert Company Method of imaging amyloid deposits
WO1999008685A1 (en) * 1997-08-18 1999-02-25 Queen's University At Kingston Phosphono-carboxylate compounds for treating amyloidosis
ES2392391T3 (es) * 1998-02-11 2012-12-10 Bhi Limited Partnership Método para modular la activación de macrófagos
US6329356B1 (en) 1998-04-10 2001-12-11 Neurochem, Inc. Phosphono-carboxylate compounds for treating amyloidosis
JP2002515429A (ja) * 1998-05-15 2002-05-28 ネウロケム、インク ニューロン細胞死を調節する方法
AU2006203051C1 (en) * 1998-05-15 2009-01-22 Bhi Limited Partnership Use of amyloid inhibitors for modulating neuronal cell death
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6310073B1 (en) 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
AU2005203635B2 (en) * 1999-05-24 2008-08-07 Bellus Health (International) Limited Methods and compounds for inhibiting amyloid deposits
US6562836B1 (en) * 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
WO2001003680A2 (en) * 1999-07-09 2001-01-18 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
WO2001085093A2 (en) * 1999-12-23 2001-11-15 Neurochem, Inc. Compounds and methods for modulating cerebral amyloid angiopathy
DE60219926T2 (de) * 2001-08-08 2007-11-22 Pentraxin Therapeutics Ltd. Wirkstoff zur entfernung einer unerwünschten proteinpopulation aus dem plasma
JP2006512417A (ja) * 2002-12-24 2006-04-13 ニューロケム （インターナショナル） リミテッド β−アミロイド関連疾患の治療のための治療用製剤
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US8044100B2 (en) 2004-12-22 2011-10-25 Bellus Health Inc. Methods and compositions for treating amyloid-related diseases
DE602006011299D1 (de) * 2005-04-07 2010-02-04 Astrum Therapeutics Pty Ltd Verbindungen zur behandlung von amyloidose und verhinderung des tods von beta-zellen bei diabetes mellitus typ 2
TW200716088A (en) 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
CA2634871A1 (en) 2005-12-22 2007-11-08 Neurochem (International) Limited Treatment of renal disorders, diabetic nephopathy and dyslipidemias
FI3851447T3 (fi) 2006-10-12 2023-11-15 Bellus Health Inc Menetelmiä, yhdisteitä, koostumuksia ja vehikkeleitä 3-amino-1-propaanisulfonihapon vapauttamiseksi
JP2010513219A (ja) * 2006-12-22 2010-04-30 ベラス ヘルス （インターナショナル） リミテッド 腎臓の疾患、糖尿病性腎症及び脂質代謝異常の治療
KR20120087878A (ko) 2009-08-10 2012-08-07 비에이치아이 리미티드 파트너쉽 1,3-프로판디설포닉 애시드의 수송을 위한 방법, 화합물 및 조성물
CN114805211A (zh) 2017-03-21 2022-07-29 润佳（苏州）医药科技有限公司 同位素富集3-氨基-1-丙磺酸衍生物、药物组合物及其用途
US20220168327A1 (en) * 2019-02-25 2022-06-02 The Australian National University Compounds for Treating and Preventing Net Associated Complications
WO2023212289A1 (en) 2022-04-28 2023-11-02 Alzheon, Inc. Tramiprosate for treating apoe4-related diseases
WO2024119183A1 (en) 2022-12-02 2024-06-06 Alzheon, Inc. Methods for treating neurodegenerative disorders with tramiprosate

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437834A1 (fr) * 1978-10-04 1980-04-30 Lejeune Jerome Compositions pharmaceutiques a base de l-serine ou de glycine
US4919915A (en) * 1987-03-03 1990-04-24 Paul Averback Method for detecting the ability to prevent red-to-green congophilic birefringence
US4847082A (en) * 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
WO1988009171A1 (en) * 1987-05-19 1988-12-01 Baylor College Of Medicine Phosphoethanolamine for treatment of alzheimer's disease
IT1205042B (it) * 1987-05-28 1989-03-10 Crinos Industria Farmaco Composizione farmaceutica ad attivita' terapeutica per il trattamento della demenza senile di tipo alzheimer
JPH01171638A (ja) * 1987-12-25 1989-07-06 Kanegafuchi Chem Ind Co Ltd 血清アミロイドａ蛋白用吸着体
JP2587842B2 (ja) * 1987-12-09 1997-03-05 株式会社ニチレイ 神経疾患治療・予防剤
DK505488D0 (da) * 1987-12-21 1988-09-09 Bar Shalom Daniel Middel og anvendelse af samme
US4968678A (en) * 1988-02-19 1990-11-06 Eli Lilly And Company Tetrazole excitatory amino acid receptor antagonists
EP0330353B1 (en) * 1988-02-19 1993-04-07 Eli Lilly And Company Tetrazole excitatory amino acid receptor antagonists
JPH0627072B2 (ja) * 1988-09-13 1994-04-13 呉羽化学工業株式会社 アミノ安息香酸誘導体を有効成分とする生体内抗酸化機構調節剤
JPH0667472B2 (ja) * 1988-11-28 1994-08-31 鐘淵化学工業株式会社 血清アミロイドｐ蛋白用吸着体
US5061721A (en) * 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
DE4004978A1 (de) * 1990-02-19 1991-08-22 Nmi Naturwissenschaftl U Mediz Praeventive therapie fuer morbus alzheimer
JPH0725786A (ja) * 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
US5242932A (en) * 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
US5137873A (en) * 1990-07-27 1992-08-11 The Children's Medical Center Corporation Substance p and tachykinin agonists for treatment of alzheimer's disease
CA2104594C (en) * 1991-02-22 2004-05-11 Howard K. Shapiro Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
US5164295A (en) * 1991-03-06 1992-11-17 The Upjohn Company Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds
US5192753A (en) * 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
US5705401A (en) * 1991-11-12 1998-01-06 The University Of Melbourne Method of assaying for alzheimer's disease
US5276059A (en) * 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation

Also Published As

Publication number Publication date
EP1614416A2 (en) 2006-01-11
JP2004189757A (ja) 2004-07-08
JP3666818B2 (ja) 2005-06-29
EP1060750A3 (en) 2003-03-26
EP0691844A1 (en) 1996-01-17
EP1060750B1 (en) 2005-12-07
ATE311864T1 (de) 2005-12-15
WO1994022437A3 (en) 1995-02-09
CA2159326A1 (en) 1994-10-13
DE69434571D1 (de) 2006-01-12
WO1994022437A2 (en) 1994-10-13
ES2251935T3 (es) 2006-05-16
EP1614416A3 (en) 2009-07-01
EP1060750A2 (en) 2000-12-20
JP4187072B2 (ja) 2008-11-26
DE69434571T2 (de) 2006-08-03
CA2159326C (en) 2000-05-30
JPH08508260A (ja) 1996-09-03

Similar Documents

Publication Publication Date Title
DK1060750T3 (da) Propan-1,3-disulfonsyre og dens farmaceutisk acceptable salte til behandling af amyloidose
DK0814842T3 (da) Fremgangsmåde til behandling af amyloidose
NO881940L (no) 4-aminokinolin-derivater og deres anvendelse som legemidler.
FI953467A0 (fi) Aminohappojohdannaisia, näitä yhdisteitä sisältävät lääkeaineet ja menetelmä niiden valmistamiseksi
ATE449174T1 (de) Neue peptide
DE3585556D1 (de) Pharmazeutische zusammensetzungen, welche ein dipeptid enthalten.
DK132287D0 (da) Anvendelse af n-substitueret isobutyramid i racemisk (r,s)-form eller i venstredrejende optisk aktiv (s)-form eller et salt heraf til fremstilling af et laegemiddel mod obesitet
KR950032275A (ko) 시클로펩티드 유도체 및 이의 제조방법
JPH02250895A (ja) 神経調節ペプチド
DE59209858D1 (de) Aminosäurederivate
RU96109375A (ru) Антитромботические азациклоалкилалканоилпептиды и псевдопептиды
DK0642791T3 (da) Anvendelse af aminosyrer med forgrenet kæde til fremstilling af et lægemiddel til behandling af tardiv dyskinesi
NO894720L (no) Farmasoeytisk aktivt protein.
US4766109A (en) Hydrophobic peptides
ES421854A1 (es) Procedimiento para la preparacion de cloruro de lisino-cal-cio.
NO913644D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
KR920700199A (ko) 머캅토-아실아미노산
EA200300900A1 (ru) Замещенные амины (варианты), способ их получения и их применение в качестве ингибиторов транспорта глицина (варианты), композиция (варианты), промежуточный иодид и способ его получения, способ лечения пациента (варианты)
Armer Inhibitors of mammalian central nervous system selective amino acid transporters
RU95117518A (ru) Способ лечения аденоидита
CY1106694T1 (el) Σουλφοναμιδια και παραγωγα αυτων που ρυθμιζουν τη δραστικοτητα ενδοθηλινης
ATE6639T1 (de) Ein gereinigtes polypeptid, ein verfahren zu dessen herstellung, dessen anwendung und das enthaltende pharmazeutische praeparat.
NO951100L (no) 2-amino-4-fenyl-4-oksosmörsyrederivater med kynurinase- og/eller kynurenin-3-hydroksylase-inhiberende aktivitet
RU96104214A (ru) Способ лечения транссудативных форм центральных хориоретинальных дистрофий
RU93005233A (ru) Гетероциклические соединения, способ их получения, фармацевтический препарат и способ лечения возбуждаемых аминокислотой рецепторов, методы их изготовления